Try our beta test site
2137 studies found for:    Bevacizumab
Show Display Options
Rank Status Study
1 Terminated Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue
Condition: Keloid
Intervention: Biological: bevacizumab
2 Completed Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome
Condition: Glaucoma
Interventions: Drug: Bevacizumab;   Drug: Mitomycin C
3 Unknown  Bevacizumab 0.500MG Intravitreal There Isn't Lower Than 0.625MG in the Treatment of ROP Type 1
Condition: Retinopathy of Prematurity
Intervention: Procedure: Injection of bevacizumab intravitreal (Avastin)
4 Completed Subconjunctival Bevacizumab and Recurrent Pterygium
Condition: Recurrent Pterygium
Intervention: Drug: Bevacizumab
5 Unknown  Intralesional Bevacizumab Injection on Primary Pterygium
Conditions: Pterygium;   Inflammation
Interventions: Drug: Intralesional injection of bevacizumab;   Drug: Topical antihistamine and vasoconstrictor
6 Unknown  89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: 89Zr-bevacizumab
7 Completed
Has Results
A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Head and Neck Cancer;   Squamous Cell Carcinoma
Interventions: Drug: Cetuximab;   Drug: Bevacizumab
8 Unknown  Eye Injections of Bevacizumab to See if Medication Helps to Lower Risk of Scar Tissue Development in the Retina and Repeated Retinal Detachment.
Conditions: Retinal Detachment;   Vitreoretinopathy Proliferative
Intervention: Drug: Bevacizumab
9 Active, not recruiting Bevacizumab in Treating Patients With Angiosarcoma
Condition: Sarcoma
Intervention: Biological: Bevacizumab
10 Active, not recruiting Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
Condition: Neuroblastoma
Intervention: Drug: Bevacizumab, Irinotecan and Temozolomide
11 Completed Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Bevacizumab, Abraxane
12 Unknown  Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment
Conditions: Intravitreal Bevacizumab Injection;   Pars Plana Vitrectomy;   Tractional Retinal Detachment;   Diabetic Retinopathy
Intervention: Drug: Bevacizumab
13 Recruiting The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors
Condition: Radiation Necrosis
Intervention: Drug: Bevacizumab (Avastin®)
14 Active, not recruiting Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC
Condition: Advanced Non-squamous Non-Small Cell Lung Cancer
Interventions: Drug: Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg;   Drug: Carboplatin and Pemetrexed with Bevacizumab 15 mg/kg
15 Terminated R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   B-cell Lymphoma
Intervention: Drug: bevacizumab, Rituximab
16 Completed Bendamustine and Bevacizumab for Advanced Cancers
Condition: Advanced Cancer
Interventions: Drug: Bendamustine;   Drug: Bevacizumab
17 Completed Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma
Condition: Metastatic Melanoma
Intervention: Drug: Biochemo + bevacizumab then ipilimumab
18 Unknown  Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis
Conditions: Hemophilia;   Synovitis
Intervention: Drug: Bevacizumab intra-articular injection
19 Active, not recruiting Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Condition: Renal Cell Carcinoma
Intervention: Drug: everolimus and bevacizumab
20 Terminated
Has Results
Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer
Condition: Colon Cancer
Intervention: Drug: FOLFOX and bevacizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.